VEOS system nicely perceived on the NASS 2023 convention in america
Gross sales development in France
Ecully, Novembre 2, 2023 – Spineway Group, specialists in progressive implants for the remedy of extreme spinal pathologies, is happy to announce that its VEOS posterior spinal fixation system acquired a wonderful response from the spine implant trade on the North American Backbone Society (NASS) Congress in Los Angeles final October1.
Throughout the occasion, the Group acquired quite a few expressions of curiosity in its VEOS fixation system, which has obtained 510(okay) clearance from the Food and Drug Administration (FDA), and established contacts with potential American companions for its distribution within the USA. This progressive platform gives spine surgeons a singular modularity, because the rational group of the implant and instrument kits allows them to carry out many several types of process with a single system, whether or not in open or minimally invasive surgical procedure (MIS).
As a reminder, the VEOS vary is one in all a lot of Distimp2 merchandise that now account for a big proportion of the Group’s gross sales in France. Within the first 9 months of 2023, Distimp gross sales in France rose by 45% in contrast with 2022, pushed primarily by the success of the VEOS vary with a lot of French healthcare institutions, together with a number of College Hospitals.
This pattern ought to proceed with gross sales of the VEOS vary beginning up in Spain earlier than the tip of 2023.
Due to of those preliminary optimistic developments, Spineway shall be pursuing its growth plans, confirming its purpose of turning into an progressive participant in France and internationally, chief in much less invasive spine therapies.
Subsequent occasions: 10 November 2023: Extraordinary Common Assembly
SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES) Discover out all about Spineway at www.spineway.com
This press launch has been ready in each English and French. In case of discrepancies, the French model shall prevail.
Spineway designs, manufactures and markets progressive implants and surgical devices for treating extreme issues of the spinal column. Spineway has a world community of over 50 impartial distributors and 90% of its income comes from exports. Spineway, which is eligible for funding via FCPIs (French unit trusts specializing in innovation), has acquired the OSEO Excellence award since 2011 and has gained the Deloitte Quick 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Expertise award (2015). ISIN: FR001400BVK2 – ALSPW
Out there Tuesday via Thursday
+33 (0)806 706 060
Eligible PEA / PME
Finance & Communication
1 Press launch dated 19 October 2023, NASS Congress 18-20 October 2023, Los Angeles, USA 2 Firm acquired in 2021